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Abstract
The new coronavirus SARS-CoV-2 has rapidly spread over the world causing the disease by WHO called COVID-19. This
pandemic poses unprecedented stress on the health care system including programs performing allogeneic and autologous
hematopoietic cell transplantation (HCT) and cellular therapy such as with CAR T cells. Risk factors for severe disease
include age and predisposing conditions such as cancer. The true impact on stem cell transplant and CAR T-cell recipients in
unknown. The European Society for Blood and Marrow Transplantation (EBMT) has therefore developed recommendations
for transplant programs and physicians caring for these patients. These guidelines were developed by experts from the
Infectious Diseases Working Party and have been endorsed by EBMT’s scientific council and board. This work intends to
provide guidelines for transplant centers, management of transplant candidates and recipients, and donor issues until the
COVID-19 pandemic has passed.
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A novel coronavirus named SARS-CoV-2 of a zoonotic
origin emerged in the beginning of this year and the disease
called Coronavirus Disease 2019 (COVID-19) started
spreading worldwide. The outbreak started in Wuhan in
China and was initially mainly concentrated in Asia with a
few import cases to other parts of the world. Next, a large
number of cases started to appear in northern Italy. There-
after, the outbreak has spread to Iran, all European coun-
tries, to North America, and the rest of the world. The WHO
classified COVID-19 a pandemic on March 11. The pres-
sure on health care systems is very high in all countries
affected and increasing numbers of infected health care staff
are being reported. Many European countries have imposed
major restrictions on meetings, travel, and everyday life.
This is likely to impact greatly on the HCT and CAR T
activity in Europe as in many other parts of the world
throughout 2020, and potentially beyond.
Early in the outbreak, the Infectious Diseases Working
Party (IDWP) of the European Society for Blood and Mar-
row Transplantation (EBMT) started working on guidelines
to support transplant centers in developing strategies for
management based on existing experience. This work was
performed in collaboration with the infectious diseases
group of American Society of Transplantation and Cellular
Therapy. In addition, the IDWP started collecting patient
reports through the mechanism of the EBMT registry to
rapidly collect information about outcome of autologous and
allogeneic HCT patients developing COVID-19. The EBMT
has also started educational activities directed to physicians,
patients, and care givers through webinars. Five weekly
updates of the recommendations have now been distributed
and the current status is summarized in this paper.
COVID-19
The infection has spread very rapidly in the population of
several countries. The time from exposure to symptom
development is between 2 and 14 days (median 5 days).
Symptoms vary from no or very mild symptoms of an upper
respiratory infection to very severe resulting in the need for
intensive care and death from Acute Respiratory Distress
Syndrome (ARDS). It is becoming increasingly clear that
asymptomatic or very mildly symptomatic individuals are
important for the rapid spread of the infection in the
population. The risks both for infections and for severe
disease seem to be lower in children. Increasing age and the
presence of comorbidities, such as hypertension, cardio-
vascular disease, diabetes, and pulmonary disease, are
reported risk factors for severe disease and mortality [1–6].
Patients, who develop more severe symptoms including
respiratory failure, often progress during the 2nd week after
the start of symptoms and it is believed that this is to a great
extent due to an immune reaction in the lower airways.
Whether patients, who are immunosuppressed develop a
different form of disease is currently unclear although some
preliminary information from early cases indicate that such
can be the case. Health care workers are also at risk for
contracting COVID-19 [7].
Prevention policies and procedures
Since the COVID-19 situation varies substantially between
and within countries, we recognize that centers are mandated
to follow guidelines, policies, and procedures decided by
national authorities as well as local and institutional policies.
Avoiding exposure by adhering to recommended hygiene
procedures, isolation of SARS-CoV-2-infected individuals,
and social distancing especially for risk groups are currently
the main prevention strategies utilized in most European
countries. Limiting exposure of health care personnel and
mitigating the psychological consequences of altered and
stressful working conditions is another high priority to
ensure that appropriate capacities remain available to treat
patients in the middle term to long term.
We believe that patients having undergone HCT or are
receiving CAR T-cell therapy can require specific con-
siderations and we therefore outline some general principles
of guidance, policies, and procedures having common
themes, including but not limited to the following.
Staff
Staff with any symptoms of infection should stay at home.
Testing for SARS-CoV-2 is strongly recommended since
symptoms can be uncharacteristic and very mild. Return to
work by staff, who have recovered from COVID-19 should
follow national guidelines, usually requiring the resolution
of symptoms and two negative PCR results.
Training of staff in proper procedures, including caring
for those with suspected or confirmed infection, ensuring
adequate access to personal protection equipment and
planning for possible staff shortage are critical. Personal
protective equipment especially masks are important to
limit the spread and to reduce the risk for health care
workers to become infected. Surgical masks protect mainly
for transmission of the virus from an infected individual
while certain masks of the FFP2/3 class (those with an
exhalation valve) protect the wearer of the mask but may
not prevent from transmitting the virus. An FFP2/3 mask
without exhalation valve also prevents from transmitting
and is an alternative. Thus, correct selection of the mask and
correct use are crucial. Many staff will be working extended
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hours in highly stressful circumstances and the emotional
and psychological impact should not be underestimated.
Regular team briefings and opportunities to talk to prevent
carer fatigue should be in place.
Outpatient visits and visitors
Outpatient visits should be as much as possible either
deferred or substituted with telemedicine visits if deemed
appropriate and feasible. Staff should preferably be dedi-
cated to a COVID-19 free transplant unit and not used
interchangeably to care for COVID-19 positive patients
although in centers with a large number of COVID-19
positive patients, it is recognized that this will not be fea-
sible. It is critical that proper protective equipment is used
as recommended by national and international competent
authorities.
No visitors should be allowed in transplant units. There
might be exceptions for parents to transplanted children;
testing for SAR-CoV-2 should then be considered before
entering the ward. Repeated testing might then be neces-
sary. This will bring its own set of challenges when
attempting to have end of life conversations with families
who will not be present in person. New ways of working
and communicating with patients and families need to be
identified, such as a daily telephone round of the next of kin
to update on progress and transmit the patient’s wishes.
Patients after HCT
Considerations in HCT and CAR T-cell recipients still
being regarded as immunosuppressed or having significant
organ dysfunction. They should limit their risk of exposure
to infected individuals as much as possible and strictly
adhere to prevention practices such as hand hygiene and
social distancing. Stem cell transplant patients should
refrain from travel and if travel is deemed absolutely
necessary, travel by private car instead of any public
transportations system including train, bus, or plane is
recommended if feasible.
Physical and social isolation although a usual practice for
many transplant patients will now extend further and for a
longer period of time and local services and practices need
to be explored by the nursing staff to ensure that patients
have adequate provision to be cared for at home.
All patients, including those without symptoms, should
be triaged and tested before entering the transplant ward.
Adequate space for symptomatic patients while awaiting the
results of COVID-19 testing should be allocated preferably
separate from the transplant unit.
Patients planned to be admitted for a transplant or to
undergo CAR T-cell therapy should try to minimize the
risk by home isolation 14 days before the start of the
transplant conditioning. Unnecessary clinic visits should be
avoided.
Transplant candidates
It is recognized that patients might suffer harm if necessary
transplant and other treatment procedures are delayed due
to COVID-19. It is not possible to give clear guidelines
regarding which procedures should be delayed since the
situation is highly variable between transplant centers.
Before starting the transplant procedure, availability of
adequately trained staff, ICU beds, ventilators, as well as
availability of the stem cell product should be ensured. In
general, however, non-urgent transplants should be defer-
red as much as possible, especially for non-malignant
disorders. For those that will have delays in treatment,
signposting to appropriate local advice and support groups
is of paramount importance.
All patients should be tested for SARS-CoV-2 and the
test results should be negative before start of the con-
ditioning regardless of whether upper respiratory symptoms
are present.
A difficult question based on lack of data is deferral of
transplant candidates if they become infected with COVID-
19. At the point of consent for transplant discussions around
advanced care planning should be initiated and include the
scenario of becoming positive during the transplant process
and what steps and actions the patient and treating team
wish to take, with early conversations and plans put in place
as soon as there is a suspicion that the patient may be
COVID-19 positive. The decision has to be made based on
individual considerations taking into account the risk of the
patient associated with on one hand the delay of the pro-
cedure and on the other proceeding with conditioning. In
general, however, if a transplant candidate is diagnosed with
COVID-19 a deferral of at least 3 months is advisable, in
accordance with ECDC recommendations. However, this is
not always possible due to the risk for progression of the
underlying disease. This might be particularly pertinent for
patients waiting for CAR T-cell therapy since this is fre-
quently performed on patients refractory for other therapies
and therefore being at a very high risk for progress of the
underlying disease Therefore, in patients with high risk
disease, stem cell transplantation should be deferred until
the patient is asymptomatic and has two negative virus PCR
swabs taken at least 24 h apart. Deferral of 14 days is a
minimum but should preferably be 21 days and a new PCR
is recommended before the start of conditioning. In patients
with low-risk disease a 3-month HCT deferral is recom-
mended. Individual considerations have to be made for
CAR T-cell patients.
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In case of close contact with a person diagnosed with
COVID-19 any transplant procedures (PBSC mobilization,
BM harvest, and conditioning) shall not be performed
within at least 14, and preferably 21, days from the last
contact. Patient should be closely monitored for the pre-
sence of COVID-19, with confirmed PCR negativity before
any transplant procedure is undertaken.
Donor considerations
Access to a stem cell donor might be restricted either due to
the donor becoming infected, logistical reasons at the har-
vest centers in the middle of a strained health care system,
or travel restrictions across international borders. It is
therefore strongly recommended to have secured stem cell
product access by freezing the product before start of con-
ditioning, and, in situations when this is not possible, to
have an alternative donor as a back-up. Peripheral blood
should be preferentially used unless there is a strong indi-
cation for bone marrow.
SARS-CoV and MERS-CoV have been detected in blood,
although there have not been any reports of transmission
from donor to recipient either in transfusion of blood pro-
ducts or cellular therapies [8]. WMDA has produced
recommendations and the EBMT endorses these guidelines.
In case of diagnosis of COVID-19, donor must be
excluded from donation. At this time, it is not possible to
give recommendations when such an individual can be
cleared for donation, but 3-month deferral can be con-
sidered unless the need for donation is urgent, and case-
specific considerations should be made.
In case of close contact with a person diagnosed with
SARS-CoV-2, the donor shall be excluded from donation
for at least 28 days. Donor should be closely monitored for
the presence of COVID-19. If the patient’s need for trans-
plant is urgent, the donor is completely well, a test is
negative for SARS-CoV-2 and there are no suitable alter-
native donors, earlier collection may be considered subject
to careful risk assessment.
Donors within 28 days of donation should practice good
hygiene and be as socially isolated as feasible during this
period. Unnecessary travel should be avoided. Donors should
have been asymptomatic for at least 14 (preferably 21) days
before donation. It is recommended that donors are tested for
COVID-19 prior to starting the mobilization procedure.
Diagnosis and management of COVID-19
Diagnosis of COVID-19
Diagnostic procedures for COVID-19 should follow
national or local guidelines. It is important to note that a test
for SARS-CoV-2 in nasopharyngeal swab can be falsely
negative and needs to be repeated if there is a strong clinical
suspicion of COVID-19. The performance of testing is
better in samples from the lower than from the upper
respiratory tract. It is also important to test for other
respiratory viral pathogens including influenza and RSV
preferably by multiplex PCR.
SARS-CoV-2 infected patients
Patients, who are positive for SARS-CoV-2 should not be
treated in rooms with laminar air flow or other rooms
(HEPA) with positive pressure unless the ventilation can be
turned off. All patients positive for SARS-CoV-2 in an upper
respiratory tract sample should undergo chest imaging, pre-
ferably by CT, and evaluation of oxygenation impairment.
Routine bronchoalveolar lavage is not recommended if a
patient tested positive for SARS-CoV-2 given risk of trans-
mission amongst health care workers, unless a co-infection is
suspected. Co-pathogens should be evaluated and treated.
Treatment
Treatment of COVID-19 positive transplant recipients and
CAR T-cell patients
Currently there is no approved treatment options in Europe
and there is no available vaccine. Several drugs have been
studied in prior coronavirus outbreaks (SARS-CoV and
MERS-CoV) and though some benefit has been demon-
strated, the data are inconclusive. Remdesivir has demon-
strated in vitro and in vivo activity in animal models against
the viral pathogens MERS and SARS, which are also cor-
onaviruses and are structurally similar to SARS-CoV-2. The
limited preclinical data on remdesivir in MERS and SARS
indicate that remdesivir may have potential activity against
COVID-19 [9–11]. Remdesivir is now approved by the
FDA, and the EMA has recently granted compassionate use.
Lopinavir/ritonavir has also been used but a recently pub-
lished trial failed its primary endpoint [10, 12]. Chloroquine
and hydroxychloroquine have also been used with early data
suggesting reduction of viral load and have been used for
therapy [9, 13, 14]. Recently, several competent authorities
have expressed concerns about safety and studies have
reported opposing results. Interferon-α and -β are also being
studied.
Since an important part of the pathology seems to be
cytokine release, different therapies addressing this syn-
drome have been tested. Tocilizumab, which is approved
for cytokine release syndrome after CAR T-cell therapy,
have been used and is approved in China [15, 16]. Data on
the use of corticosteroids are contradictory. However, short-
term corticosteroid therapy was associated with lower
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mortality in immunocompetent patients with COVID-19-
associated ARDS.
Some data suggest that use of angiotensin conversion
enzyme inhibitors and angiotensin II receptor blocker
might be implicated in development of organ failure in
COVID-19 patients [17, 18] but lower mortality has also
been reported with the use of these drugs [19]. Similarly, it
has been suggested that NSAIDs might have negative
effects and therefore acetaminophen/paracetamol are pre-
ferred as anti-pyretics.
At this point no clear recommendations can be made on
specific therapies due to limited data and unknown risk vs
benefit. Even less data are available for pediatric patients.
Therapy should be given in close collaboration with spe-
cialists in infectious diseases. Despite FDA approval of
remdesivir, it is still unclear if and when it optimally should
be used. Later in the course of the infection anti-
inflammatory therapy with corticosteroids and/or tocilizu-
mab has been shown to be of value in non-transplant
patients. Supportive care is crucial including non-invasive
ventilation and anti-coagulants to prevent thromboembolic
complications, which can be frequent and severe in patients
with COVID. Treatment of viral, bacterial and fungal co-
pathogens should be optimized. It is currently recom-
mended that immunosuppressive prophylaxis/treatment is
continued since there is no data supporting reducing
immunosuppression and it might instead cause harm.
JACIE and COVID-19
In the light of substantial and ongoing disruption caused
by the international COVID-19 pandemic, which has made
normal JACIE accreditation services difficult or impos-
sible to maintain in the foreseeable future, the EBMT took
the decision to extend current accreditations by 12 months
and to give coverage to those centers that are actively
preparing for reaccreditation https://www.ebmt.org/covid-
19-and-bmt.
Even so, for centers already accredited (or preparing for
accreditation) current and recent versions of JACIE stan-
dards include extensive reference to disaster planning
within the clinical, collection (apheresis and bone marrow)
and processing sections [20]. Modifications to usual care
should be considered within the broader organization
according to ongoing quality management systems in the
program and other JACIE accreditation requirements.
JACIE is currently evaluating whether more simplified
versions of quality standards currently being applied to low
and middle income countries, such as ‘Stepwise’ or other
systems, will have value during the COVID-19 pandemic
and its aftermath which may last for many months.
Discussion
The COVID-19 pandemic has resulted in previously
unprecedented challenges to transplant programs and phy-
sicians performing stem cell transplantation. Although
WHO and other international and national authorities have
warned for the possibility of a new pandemic caused most
likely by a viral pathogen such as SARS-CoV-1, SARS-
CoV-2, a new influenza strain, or possibly a hemorrhagic
fever such as Ebola or Lassa, the health care systems were
caught unprepared for the COVID-19 pandemic. However,
enormous activity has started from the beginning of the
outbreak in China to learn more about the virus and the
disease and to disseminate this knowledge across the world,
Since the virus is new to the human population, it is likely
that before long-term virus control is achieved a large
proportion of the population will have to either have
experienced the viral infection or have been vaccinated.
Therefore, continued international collaboration is neces-
sary to increase our knowledge and thereby decrease the
risk for harm to the very vulnerable group of patients either
waiting for or having undergone the potentially life-saving
procedure of HCT or cellular therapy. Scientific organiza-
tions such as the EBMT has a responsibility to the com-
munity to help gather and disseminate information
including collecting cases of COVID-19 through its well
established registry and also to actively participate in edu-
cational activities directed to all stakeholders in the trans-
plant and cellular therapy activities.
On a national level, EBMT cannot define the specifics of
how centers need to work internally and with each other
within networks and public health and the broader context
of health care. Some of aspects of networking and working
with public health and other stakeholders may not come
easy or be straightforward. However, irrespective of center,
nation or health service, transplant teams should work to put
patients’ interests first, values which are central to the
Mission and Vision of EBMT.
Finally, we recommend that you follow https://www.
ebmt.org/covid-19-and-bmt and participate in the EBMT
IDWP prospective survey of the impact of COVID-19 on
patients undergoing HCT and cell therapy.
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